Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

New MS diagnostic criteria put to the test in Real-World study

NCT ID NCT07492667

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study compares the 2024 and 2017 McDonald criteria for diagnosing multiple sclerosis (MS) in 100 patients with symptoms suggestive of MS. Researchers will see if the newer criteria catch more cases early without extra tests. The goal is to improve diagnosis and guide future updates.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this could help doctors diagnose multiple sclerosis earlier and more accurately using the latest criteria.
What could go wrong
This is an observational study, not a treatment trial. It may not change practice if the new criteria don't prove clearly better in real-world use.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 100 people

The number the study aims to enrol. It can still change while the study runs.

Started

Sep 2025

Expected to finish

Dec 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Patients with a clinical or radiological event / lesion suggestive of multiple sclerosis after ruling out differential diagnosis. Patients from the Lorraine region in France, being referred to the University Hospital of Nancy for diganostic assessment

Ages

Children (under 18), adults (18 to 64) and older adults (65 and over)

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Patients covered by French national health insurance * Consulting or hospitalized in neurology at Nancy University Hospital or Metz-Thionville Regional Hospital, Mercy site * For the first time for a clinical and/or radiological event suggestive of multiple sclerosis according to the Nancy or Mercy hospital neurologist responsible for the patient Exclusion Criteria: * Clinical and/or radiological event suggestive of something other than multiple sclerosis, such as neuromyelitis optica spectrum disorder, pathologies associated with anti-MOG antibodies, sarcoidosis, syndromes associated with anti-neuronal antibodies, etc., as well as vascular, infectious, tumor, or paraneoplastic disorders * Inability to perform at least one brain MRI during initial management (contraindication to this examination).

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Event suggestive of multiple sclerosis are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    2 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Centre Hospitalier Régional Universitaire

    RECRUITING

    Nancy, Lorraine, F-54000, France

  • Centre Hospitalier Régional de Metz, site Mercy

    RECRUITING

    Ars-Laquenexy, Lorraine, F-57530, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.